TEVA PHARMACEUTICAL INDUSTRIES LIMITED Available-for-sale Securities, Gross Unrealized Loss
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) reported Available-for-sale Securities, Gross Unrealized Loss of $20.00 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-02-19.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2019-02-19
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED available-for-sale securities, gross unrealized loss for the quarter ending 2017-12-31 was $0.00.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED available-for-sale securities, gross unrealized loss for the quarter ending 2017-09-30 was -$6.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED available-for-sale securities, gross unrealized loss for fiscal 2017 was $20.00M, a 53.49% decline from fiscal 2016.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED available-for-sale securities, gross unrealized loss for fiscal 2016 was $43.00M.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 0 month | Available-for-sale Securities, Gross Unrealized Loss 3 month | Available-for-sale Securities, Gross Unrealized Loss 6 month | Available-for-sale Securities, Gross Unrealized Loss 9 month | Available-for-sale Securities, Gross Unrealized Loss 12 month |
|---|---|---|---|---|---|
| 2017-12-31 | $20.00M 10-K · filed 2018-02-12 | $0.00 derived: 10-K 12 month − 6-K 9 month · filed 2019-02-19 | -$6.00M derived: sum of 2 quarters · filed 2019-02-19 | $20.00M 10-K · filed 2019-02-19 | |
| 2017-09-30 | -$6.00M derived: 6-K 9 month − 6-K 6 month · filed 2017-11-02 | $20.00M 6-K · filed 2017-11-02 | |||
| 2017-06-30 | $26.00M 6-K · filed 2017-08-03 | ||||
| 2017-03-31 | $32.00M 6-K · filed 2017-05-11 | ||||
| 2016-12-31 | $43.00M 6-K · filed 2017-11-02 | $43.00M 10-K · filed 2018-02-12 | |||
| 2016-09-30 | $72.00M 6-K · filed 2016-11-15 | ||||
| 2016-06-30 | $34.00M 6-K · filed 2016-08-04 | ||||
| 2016-03-31 | $35.00M 6-K · filed 2016-05-09 | ||||
| 2015-12-31 | $21.00M 20-F · filed 2017-02-15 | ||||
| 2014-12-31 | $26.00M 20-F · filed 2016-02-11 |